AlphaQuest LLC Purchases 61,989 Shares of Spyre Therapeutics, Inc. $SYRE

AlphaQuest LLC lifted its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 1,485.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,163 shares of the company’s stock after purchasing an additional 61,989 shares during the quarter. AlphaQuest LLC owned about 0.11% of Spyre Therapeutics worth $1,109,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of SYRE. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Spyre Therapeutics by 1.1% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 110,456 shares of the company’s stock valued at $1,851,000 after purchasing an additional 1,172 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Spyre Therapeutics in the 3rd quarter worth approximately $310,000. Tower Research Capital LLC TRC boosted its holdings in shares of Spyre Therapeutics by 182.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after acquiring an additional 3,725 shares during the last quarter. Man Group plc acquired a new position in Spyre Therapeutics during the second quarter valued at $162,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Spyre Therapeutics by 300.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 223,320 shares of the company’s stock valued at $3,343,000 after buying an additional 167,487 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Spyre Therapeutics

In related news, CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $30.68, for a total value of $460,200.00. Following the transaction, the chief executive officer directly owned 671,907 shares in the company, valued at $20,614,106.76. This trade represents a 2.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Mizuho raised shares of Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Citigroup initiated coverage on Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective on the stock. Wall Street Zen raised shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a report on Monday, December 29th. Finally, Jones Trading upgraded Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a report on Monday, December 1st. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $53.88.

Spyre Therapeutics Price Performance

SYRE stock opened at $31.98 on Monday. The business’s 50-day moving average is $32.27 and its two-hundred day moving average is $23.47. The firm has a market capitalization of $2.48 billion, a P/E ratio of -14.60 and a beta of 3.15. Spyre Therapeutics, Inc. has a 1 year low of $10.91 and a 1 year high of $35.31.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.53. On average, analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.